This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • Investigation of pathways regulating cell survival...
Clinical trial

Investigation of pathways regulating cell survival and early antiangiogenic response to single agent Rapamycin in Renal Cancer

Read time: 1 mins
Last updated:27th Jan 2011
Drugs that inhibit the mTOR enzyme have clinical activity in renal cancer, causing significant delay in disease progression, although with a low incidence of objective tumour regressions. This trial aims to identify early indicators of disease response or resistance.
Category Value
Study start date 2011-01-27

View full details